TriAgenics says it is approaching a key turning point as it prepares to enter FDA review for a new preventive dental treatment designed to stop wisdom teeth from forming.
For decades, wisdom tooth care has largely relied on surgical extraction, often involving anesthesia, recovery time and high costs for patients. Dentists typically refer these cases to oral surgeons, which can mean lost revenue and reduced continuity of care. Despite the frequency of the procedure, the standard approach has remained largely unchanged.
TriAgenics aims to disrupt this model with its patented Zero3 TBA treatment. Instead of removing wisdom teeth after they emerge, the company’s approach is intended to prevent them from developing in the first place. The minimally invasive procedure takes about one minute and can be performed by general dentists without surgery, according to the company.
The treatment is positioned as preventive care for children between the ages of 6 and 12. TriAgenics says the ability to offer Zero3 could create a significant new revenue stream for dental practices, estimating that a general dentist performing 10 procedures per month could generate up to $300,000 in additional annual revenue.
The potential market is sizable. The wisdom tooth care sector is estimated at nearly $5 billion annually, with roughly 5 million patients undergoing related procedures each year.
TriAgenics is led by executives with experience at companies such as IBM and Align Technology. The company says it holds 37 patents covering the Zero3 technology, which it believes provides strong protection against competitors.
As it moves toward FDA review, TriAgenics is opening investment opportunities to the public. The company is also offering early investors bonus shares of up to 13%, with the promotion set to expire on February 3.
If approved, the company says its approach could reshape how dentists manage wisdom teeth, offering a non-surgical alternative that addresses safety, recovery and cost concerns for patients and parents alike.
